Fostroxacitabine Bralpamide Hydrochloride is a small molecule commercialized by Medivir, with a leading Phase II program in Hepatocellular Carcinoma. According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Fostroxacitabine Bralpamide Hydrochloride’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Fostroxacitabine Bralpamide Hydrochloride is expected to reach an annual total of $76 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Fostroxacitabine Bralpamide Hydrochloride Overview

fostroxacitabine bralpamide (MIV-818) is under development for the treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. The drug candidate is administered through the oral route as a capsule. It is a prodrug of troxacitabine. It is liver-targeted nucleoside prodrug. It acts by targeting DNA polymerase.

Medivir Overview

Medivir is a pharmaceutical company that carries out the development and commercialization of innovative treatments for cancer. The company products include fostroxacitabine bralpamide (fostrox), remetinostat, miv-711, birinapant/IGM-9427, Xerclear (Zoviduo), USP-1/TNG348, USP-7 and mbli/met-x. Medivir product indications include hepatocellular carcinoma, cutaneous t-cell lymphoma (mf), basal cell carcinoma, squamous cell carcinoma, osteoarthritis, solid tumors, labial herpes, cancer and infection. It distributes products through licensing agreements with various partners including Tango Therapeutics, Ubiquigent Limited, and Infex Therapeutics. Medvir is headquartered in Huddinge, Sweden.
The company reported revenues of (Swedish Krona) SEK7.6 million for the fiscal year ended December 2023 (FY2023), an increase of 73.2% over FY2022. The operating loss of the company was SEK91.4 million in FY2023, compared to an operating loss of SEK87.4 million in FY2022. The net loss of the company was SEK89.3 million in FY2023, compared to a net loss of SEK88.8 million in FY2022. The company reported revenues of SEK0.5 million for the first quarter ended March 2024, a decrease of 88.7% over the previous quarter.

For a complete picture of Fostroxacitabine Bralpamide Hydrochloride’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.